Featured News

More and more evidence is showing what many have long suspected: maintaining a truly gluten-free diet may not be possible.

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe…

There is currently no easy way to diagnose celiac disease in patients already following a gluten-free diet. In order for celiac disease blood tests to be accurate, patients on a…

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a…

Researchers are collecting blood samples to help develop new diagnostics that may not require gluten ingestion or a biopsy to confirm the diagnosis. 

ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.

On August 13th, 2019, Innovate Biopharmaceuticals, Inc. (Innovate) announced the first patient has been dosed in its Phase 3 clinical trial for patients with celiac disease. The CeD LA 3001…

Researchers are collecting blood samples to learn more about the antigens that cause certain T cells to trigger intestinal damage in celiac disease patients. Complete a 30-minute study from home & be compensated $50 for your time.

ImmunsanT announces end of its global Phase 2 clinical trial for its Nexvax2 drug candidate. Early results indicate gluten-exposure protection similar to placebo.

If you have celiac disease and currently have kidney stones, or have had kidney stones in the past, you may be eligible for a clinical research study!